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Background: In current practice, immunotherapy has been established as an adjuvant rescue therapy for
cervical cancer treatment after standard concurrent chemoradiotherapy (CCRT) with tumor recurrence.
Carcinoma of the cervix is a relatively chemotherapy-resistant disease. Patients with recurrent cervical
cancer have signiﬁcantly reduced life expectancy, and fewer than 20% of patients survive for 1 year.
Therefore, we tried using CCRT after priming and booster immunomodulatory therapy [i.e., immu-
nochemoradiotherapy, (ICRT)].
Case reports: In the ﬁrst report, a 34 year-old female diagnosed with International Federation of Gyne-
cology and Obstetrics (FIGO) stage IIA cervical cancer with pathological proof of poorly differentiated
squamous cell carcinoma was treated with radical surgery. Two years later, she experienced progressive
weakness and numbness in her right leg. Computed tomography showed a mass of 8 cm  7 cm in her
right lower pelvis and presacral area with encasement of the right middle ureter. In addition, right
hydronephrosis and a metastatic lymph node were suspected in the right iliac vessels. She received
standard CCRT with “add on” immunomodulatory agents as a radiosensitizer to augment ICRT. The
priming immunomodulatory agents included picibanil [O (i.e., OK-432)], mixed Cervarix (Glax-
oSmithKline, London, England) or Gardasil (Merck and Co., Inc., Kenilworth, NJ, USA) viral-like particle
vaccine (V) on day 1, and aldesleukin [A (i.e., interleukin-2)] on Day 2. She also started concurrent
radiotherapy and palcitaxol (80 mg/m2) on Day 2 and boostered OVA (i.e., picibanil, viral-like particle
vaccine, and aldesleukin) again on Day 4 and Day 5. After the ICRT treatment, remarkable improvements
occurred by lower sacral pain, regression of the pelvic tumor, and decreased squamous cell carcinoma
antigen (SCC-Ag) levels from 33.8 ng/mL to normal. The second case report is a 66-year-old female with
FIGO stage IIA cervical adenocarcinoma. She underwent staging surgery, followed by CCRT. She ﬁrst had a
relapse on the supraclavicle node 2 years before receiving CCRT. A left axilla mass was noted 6 years
before she started the priming and booster ICRT treatment. Both patients have been disease-free for >
5 years since receiving CCRT.
Conclusion: We reported two patients with cervical cancer recurrence after conventional therapy. We
combined CCRT and ICRT to augment the host cells' immunosurveillance and reach durable response more
than 5 years mimic long-term progression-free survival. These two patients showed promising results.
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Recurrent cervical cancer after surgery and/or radiotherapy has
a high rate of mortality and morbidity. The 5-year survival rates
reported in patients with relapsed cervical cancer after radical
surgery or radiotherapy range between 3.2% and 13%. Tumory InvasiveTherapy. PublishedbyElsevierTaiwanLLC. This isanopenaccessarticleunder theCC
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one-half of patients. Curative options for these patients are either
high-dose radiotherapy or pelvic exenteration.2,3 Compared to
pelvic exenteration, high-dose radiotherapy or concurrent chemo-
therapy (CCRT) may be more suitable for younger patients. Treat-
ment of advanced or persistent cervical cancer includes
radiotherapy and chemotherapy. However, at the present time,
there is no effective treatment for metastatic disease and re-
currences. Experimental data from multiple cancer models have
provided sufﬁcient evidence that the effects of ionizing radiation
may contribute to systemic antitumor immunity.4 Therefore, we
attempted to use standard CCRT after priming and boosting with
immunomodulatory therapy [i.e., immunochemoradiotherapy,
(ICRT)] as a combination therapy to augment host cells' immuno-
surveillance in patients with relapsed cervical cancer. We present
two patients in whom this innovative approach was successful. It
may become a novel treatment option for advanced cervical cancer
or recurrent cervical cancer in the future.
Case Reports
Case 1
A 34 year-old female with no known systemic disease was
diagnosed with cervical cancer. She underwent type III radical
surgery. The pathological examination revealed poorly differenti-
ated squamous cell carcinoma, International Federation of Gyne-
cology and Obstetrics (FIGO) stage IIA (i.e., T2aN0M0). Two years
later, she was experiencing progressive weakness and numbness in
her right leg. Computed tomography (CT) showed a pelvic mass,
8 cm  7 cm, in the right lower pelvis and presacral area with
encasement of the right middle ureter. In addition, right hydro-
nephrosis and a metastatic lymph node were suspected in the right
iliac vessels. The patient received standard CCRT with the prime-
boost “add on” immunomodulatory agents picibanil (i.e., OK-432),
aldesleukin [i.e., interleukin-2 (IL-2)], levamisole, and human
papillomavirus (HPV) 6, 11, 16, 18 recombinant vaccine (Gardasil;
Merck and Co., Inc., Kenilworth, NJ, USA) or HPV 16, 18 (Cervarix;
GlaxoSmithKline, London, England ) were initiated as one vial
subcutaneous administered the immunomodulatory therapeutic
regimen, respectively. Picibanil (OK-432) and aldesleukin (IL-2) are
well-studied immunomodulators for treating melanoma, gastric
cancer, and many other cancers.5 Levamisole and HPV 6, 11, 16, 18
recombinant vaccine (i.e., Gardasil) and/or HPV 16, 18 recombinant
vaccine (i.e., Cervarix) have been used for adjuvant therapeutic
vaccination. The use of levamisole as an immunostimulant has been
successful in controlling certain diseases. Levamisole is used in
combination with a vaccine to improve its immunogenic effect
in inducing dendritic cell maturation and the secretion of IL-12 and
IL-10.6 External radiation therapy (RT) was also administered in the
ﬁrst 2 months with subsequent integrated chemotherapy, after two
cycles of paclitaxol (80 mg/m2) and/or cisplatin (40 mg/m2). After
completing treatment, remarkable improvements in sacral pain,
regression of the pelvic tumor, and decrease in SCC-Ag levels were
observed (Figure 1).
Figure 1 shows the SCC-Ag level of the ﬁrst patient. Her SCC level
remained elevated until the completion of the immunotherapy. The
patient also received a series of CT scans to evaluate the severity
and progression of the tumor. Images of the recurrent tumor were
compared before ICRT. Three months after the treatment, a cystic
change and a decrease in the size of the tumor had occurred
(Figures 2A and 2B, respectively). Two years after she had been
treated with ICRT, the masses totally regressed to achieve durable
response and there was no deﬁnite metastasis to the soft tissues of
the neck, lung, chest wall, ribs, lymph nodes, or any part ofintestines or bony structure (Figure 2C). These ﬁndings suggest that
she had achieved a complete remission of cervical cancer, after
undergoing priming and booster ICRT.
Case 2
A 66-year-old female was diagnosed with cervical adenocarci-
noma, FIGO stage IIA (i.e., T2aN1M1). She underwent surgery and
CCRT. Three years before she received CCRT, supraclavicular node
and axilla lymph node metastatic carcinoma was noted. Metastatic
nodes and a movable mass at the left axilla were noted 6 years
before she was administered the immunotherapies OK-432 and
HPV 6,11,16, 18 or HPV 16,18 recombinant vaccines (i.e., Gardasil or
Cervarix, respectively). Two months later, she received another
immunotherapy treatment with OK-432 and IL-2. She is stable now
and has been disease-free for > 5 years. Because of successful du-
rable response in relapse of cervical cancer after standard CCRT, our
team was approved to complete preclinical model prime-boost
vaccination to obtain promising results.
Thus, we reported two retrospective cases of patients who
received CCRT with mixed prime-boost “add on” OK-432 and HPV
6, 11, 16, 18 or HPV 16, 18 recombinant vaccines (i.e., Gardasil or
Cervarix, respectively) immunomodulatory agents. Figure 3 shows
a shrunken metastatic axillary mass at 3 months after additional
CCRT, following ICRT in the second patient.
The Institutional Review Board of Chang Gung Memorial Hos-
pital (Taoyuan, Taiwan) understood and approved our overall
treatment (approval number, 97-0505B). The patients have given
their consent for their case reports to be published.
Discussion
We reported two cases of local advanced cervical cancer with
recurrence after conventional therapy by either surgery and/or
CCRT. We combined CCRT and/or ICRT to augment the host cells'
immunosurveillance. These two patients overall show promising
results, and both patients are free of disease and mimic
progression-free survival for more than 5 years. We currently do
not know to rescue the standard treatments and/or “add on” prime-
boost immunotherapy for recurrent and/or metastatic cervical
cancers have focused on pelvic exenteration. This approach,
although morbid, remains the only curative option for locally iso-
lated recurrent disease. When pelvic exenteration is not generally
appropriate because of metastatic disease, palliative radiation has
been used. However, more novel discoveries about tumor immu-
nity and experimental data from multiple cancer models have
provided sufﬁcient evidence that the effects of ionizing radiation
may contribute to systemic antitumor immunity.4 Previous reports
have shown consistent promising results in preclinical models of
cervical cancer therapeutic vaccines.7e12 To date, even in an adju-
vant setting, the efﬁcacy of radioimmunotherapy for recurrent local
invasive cervical cancer has not been well determined and the
concept of immunotherapy combined with chemotherapy was also
halted at the preclinical stage.7 These results prompted us to
initiate the current study. However, these results are preliminary
and further studies are needed to substantiate the clinical utility of
these methods. We propose three mechanisms.
First mechanism: radiation therapy converts the tumor into an in
situ vaccine
“Abscopal effects” may explain the lasting effect in reducing the
possibility of recurrence. Mole13 emphasize that all cells in the body
are interdependent and damage to one cell affects the organism as
a whole. Therefore, local radiation has an effect, and other local
Figure 1. The graph shows the change in the squamous cell carcinoma (SCC) tumor marker level in the ﬁrst patient. Immunochemoradiotherapy (ICRT) was initiated, and the SCC
marker level remained elevated until the end of immunotherapy.
Figure 2. (A) Before beginning immunochemoradiotherapy (ICRT), recurrent cervical cancer is visible in the patient's right lower pelvis and presacral space. The transverse view of
the pelvis on the computed tomography (CT) image shows two large tumor masses, the sizes of which are 5.00 cm  5.50 cm and 3.64 cm  4.44 cm. (B) The recurrent tumor mass,
after priming and boosting every 3 days with OA-OA and concurrent chemoradiotherapy (CCRT). The treatment-mediated cystic change by the 3rd month after initiating ICRT and
CCRT. The transverse view of the pelvis on the CT image shows that two tumor masses remain. One tumor, 6.90 cm  4.29 cm, is a cystic mass with an irregular wall and engorged
vessels. It is in the right pelvis and has invaded the urinary bladder and rectum. The other tumor has atrophied to 3.37 cm  4.40 cm. (C) The transverse view of the pelvis on the CT
image shows that the tumor masses have vanished. OA ¼ picibanil/aldesleukin.
Figure 3. The computed tomography (CT) image of a shrunken metastatic axillary mass after additional concurrent chemoradiotherapy (CCRT), following ICRT with picibanil
(OK-432) and human papillomavirus (HPV) 6, 11, 16, 18 recombinant vaccine (Gardasil; Merck and Co., Inc. Kenilworth, NJ, USA).
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nomenon could be called an “abscopal effect.”13,14 Many mecha-
nisms of abscopal effects have been discussed. The most accepted
mechanism is related to the immune system, especially the
“danger” model of immunity originally proposed by Matzinger in1994.15,16 Matzinger postulated that the immune systemdrather
than differentiating “self” from “nonself”dresponds to “danger
signals” that occur as a consequence of tissue damage. Apoptosis
and necrosis induced by environmental stress, pathogens, chemo-
therapy, and radiation can create a milieu that elicits “danger
Y.-H. Lin et al. / Gynecology and Minimally Invasive Therapy 5 (2016) 127e131130signals.” Based on this theory, radiation may induce cancer
apoptosis and/necrosis, which releases exosomes and elicit an in-
ﬂammatory response locally and thereby induce T-cell activation
against tumor antigens. These antigens then circulate and may be
responsible for the abscopal effects seen during RT. A similar hy-
pothesis has also been described by Demaria et al17 who demon-
strated that the abscopal effect induced in tumors treated by
radiation appears to be immune-mediated, and that T-cells are
required for the distant effects. Dewan also found in two preclinical
carcinomamodels that fractionated radiotherapy, instead of single-
dose radiotherapy, induces an abscopal effect when combined with
anti-CTLA-4 antibody.18
Second mechanism: the combination of immunotherapy and
chemotherapy may cause a synergistic therapeutic effect
Cytotoxic chemotherapy remains one of the most widely avail-
able treatment options for cancer. The efﬁcacy of chemotherapy is
unfortunately limited; in particular, cures are rarely achieved for
solid tumors. Immunotherapy is a more experimental treatment
method aimed at mobilizing the body's immune cells to attack
tumor cells; however, it is also rarely curative. Few studies have
investigated combining chemotherapy and immunotherapy, largely
because the two forms of treatment are considered antagonistic in
the standard regimen.
Two assumptions contribute to this view. First, most chemo-
therapies kill the target cells by triggering the process of pro-
grammed cell death (i.e., apoptosis). This mode of cell death is
regarded as nonstimulatory or tolerogenic (i.e., tolerance inducing).
In general, chemotherapeutic agents have an immunosuppressive
function; however, they provide an immunomodulatory thera-
peutic window to elicit tumor-speciﬁc T-cells to generate an
excellent anticancer response. Thus, apoptosis-inducing chemo-
therapy would be expected to induce a state of nonresponsiveness
in cytotoxic T-lymphocytes that could otherwise potentially
destroy tumor cells.
Second, lymphocyte depletion (i.e., lymphopenia) is a common
adverse effect of many anticancer drugs and/or radiation, which is
assumed to be detrimental to any potential immune response.
However, recent studies challenge both of these assumptions, and
new mechanisms have been raised.7
One mechanism that has been postulated in an attempt to
explain the synergistic effects of chemotherapy and immuno-
therapy is that chemotherapeutic drugs may enhance the anti-
tumor effects of immunotherapy by acting directly on the tumor
and host environment, and thereby minimizes the drugs' immu-
nosuppressive effects. Some studies have demonstrated that
certain drugs maymodify the immunogenicity of tumor cells. Some
chemotherapeutic agents may cause tumor cells to become highly
immunogenic, while others may directly cause tumor cell death by
the release of a multitude of epitopes and exosomes for recognition
by the immune system. This factor subsequently incites an immune
response against tumor cells such as lysis by cytotoxic T-lympho-
cytes (CTLs). Moreover, chemotherapy may eliminate or reduce the
activity of regulatory T-cells and their tumoricidal activity. Other
potential mechanisms include the induction of transient lympho-
penia through chemotherapy, which may eliminate the activity of
regulatory T-cells and the stimulation of antitumor CTLs.19
Third mechanism: immunochemoradiotherapy is the future trend
To study the efﬁcacy of the combination of chemotherapy and
radiotherapy, many researchers have developed unique analytical
paradigms. We initially used picibanil (OK-432), which triggers
dendtritic cells to express many cell surface receptors such as majorhistocompatibility complex class I (MHC I), MHC II, CD1d, and /or
toll-like receptors to carry tumor-derived antigens to tumor-
draining lymph nodes to complete effective signal 1 and signal 2
immunization, after ICRT.8e12 To determine the type of interaction
between chemotherapy and radiotherapy within the radiation ﬁeld
(i.e., supra-additivity, additivity, or infra-additivity), Steel and
Peckham described isobologram analysis, which is based on the
isoeffect concept of chemoradiotherapy interaction. Independent
doseeresponse curves for chemotherapy and radiotherapy are
necessary to create a plot (i.e., isobologram).20 Other methods exist
to determine the types of additivity such as the median effect
principle and the response surface approach. The concept of addi-
tivity unfortunately is of limited use in clinical practice because the
preclinical prediction of additivity does not translate well into
clinical outcomes. Therefore, the use of this method is limited for
forming hypotheses, which need to be conﬁrmed empirically.
Shioyama et al21 used chemoradiotherapy and immunotherapy
successfully to treat a patient with a gastrointestinal stromal tumor,
and their study is the only clinical study, rather than a preclinical
study, to discuss ICRT. Even for preclinical studies, ICRT has been a
rare subject in past decades. There are many differences between
this report and our report such as the sequence of immunotherapy
and CCRT that was administered, the cancer type, and different
regimens. However, our report still illustrates the potential of
treating cancer by priming and boosting using the ICRT regimen.
We have presented two cases of recurrent cervical cancer that
was cured by innovative prime-boost immunochemoradiotherapy.
We have demonstrated proof of the concept of concurrent radio-
therapy with chemotherapy and/or immunotherapy that links
innate and adaptive immune cells to elicit a promising anticancer
response.8e10 Further studies on the efﬁcacy between different
combinations of regimens or treatment methods and their mech-
anisms are nonetheless needed.
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